Pharmacokinetic Studies with Amphetamines: Relationship to Neuropsychiatric Disorders

  • Lars-M. Gunne
  • Erik Änggård


In Sweden there has been a long-lasting epidemic of amphetamine abuse. It became evident at the end of the fifties and seems to have culminated around 1969. At that time the approximate number of intravenous abusers of high doses of amphetamine was estimated to be 10,000, the majority of whom lived in, or close to, the capital of Sweden (Inghe, 1969). In this area mainlining amphetamine abusers represented about 0.5% of the total population, corresponding to a similar percentage of heroin addicts in New York City at the same time. Since 1969 we have witnessed a rise in opiate abuse, which has gradually changed the drug scene into a more Americanlike picture. The present report deals with pharmacokinetic and clinical studies of effects of high amphetamine doses in intravenous abusers. All studies were carried out in a specialized four-bed metabolic unit, where appropriate cases were received during the period of investigation.


Acidic Urine Alkaline Urine Paranoid Psychosis Amphetamine Abuser Basic Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Angrist, B. M. and Gershon, S., 1970, “The phenomenology of experimentally induced amphetamine psychosis-preliminary observations,” Biol. Psychiat. 2: 95–107.PubMedGoogle Scholar
  2. Asatoor, A. M., Galman, B. R., Johnson, J. R., Milne, M. D., 1965, “The excretion of dexamphetamine and its derivatives,” Brit. J. Pharmacol. 24: 293.PubMedGoogle Scholar
  3. Änggård, E., Gunne, L.-M., and Nicklasson, F., 1970a, “Gas chromatographic determination of amphetamine in blood, tissue and urine,” Scand. J. Clin. Lab. Invest. 26: 137.PubMedCrossRefGoogle Scholar
  4. Änggård, E., Gunne, L.-M., Jönsson, L. E., and Nicklasson, F., 1970b, “Pharmacokinetic and clinical studies on amphetamine dependent subjects,” European J. Clin. Pharmacol. 3: 3–11.CrossRefGoogle Scholar
  5. Beckett, A., and Rowland, M., 1965, “Urinary excretion kinetics of amphetamine in man,” J. Pharm. Pharmacol. 17: 628.PubMedCrossRefGoogle Scholar
  6. Beckett, A. H., Salmon, J. A., and Mitchard, M., 1969, “The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using 14C-amphetamine,” J. Pharm. Pharmacol. 21: 251.PubMedCrossRefGoogle Scholar
  7. Bland, J. H., 1956, Disturbances of Fluid Balance. W. B. Saunders, Philadelphia and London.Google Scholar
  8. Caldwell, J., Dring, L. G., and Williams, R. T., 1972, “Norephedrine as metabolites of 14C amphetamine in urine in man,” Biochem. J. 129: 23–24.PubMedGoogle Scholar
  9. Cavanaugh, J. H., Griffith, J. D., and Oates, J. A., 1970, “Effect of amphetamine on the pressor response to tyramine. Formation of p-hydroxynorephedrine from amphetamine in man,” J. Clin. Pharmacol. Therap. 11: 656.Google Scholar
  10. Costa, E. and Groppetti, A., 1970, “Biosynthesis and storage of catecholamines in tissues of rats injected with various doses of d-amphetamines,” in: International Symposium on Amphetamines and Related Compounds (Costa, E., and Garattini, S., eds.) Raven Press, New York.Google Scholar
  11. Davidoff, E., and Reifenstein, E. C., 1937, “The stimulating action of benzedrine sulfate,” J. Am. Med. Assoc. 108: 1770–1776.CrossRefGoogle Scholar
  12. Davis, J. M., Kopin, E. J., and Axelrod, J., 1969, “Effects of urinary pH on plasma levels and metabolism of 3H-amphetamine in man,” Pharmacologist 11: 2.Google Scholar
  13. Davis, J. M., Kopin, E. J., Lemberger, L., and Axelrod, J., 1971, “Effects of urinary pH on amphetamine metabolism,” N.Y. Acad. Sci. 179: 493.CrossRefGoogle Scholar
  14. Espelin, D. E., and Done, A. K., 1968, “Amphetamine poisoning,’ New Engl. J. Med. 278: 1361.PubMedCrossRefGoogle Scholar
  15. Goldstein, M., and Contrera, J. F., 1962, “The substrate specificity of phenylethylamine β-hydroxylase,” J. Biol. Chem. 237: 1898.PubMedGoogle Scholar
  16. Griffith, J. D., Cavanaugh, J., Held, J., and Oates, J. A., 1970, Experimental Psychosis induced by the Administration of d-Amphetamine, International Symposium on Amphetamines and Related Compounds ( Costa and Garattini, eds.) Raven Press, New York.Google Scholar
  17. Gunne, L.-M., 1967, “The Urinary output of d-and l-amphetamine in man,” Biochem. Pharm. 16: 863–869.PubMedCrossRefGoogle Scholar
  18. Gunne, L.-M., and Sandberg, C. G., 1967, Stereoselective metabolism of amphetamine in man., in: Abuse of Central Stimulants, Sjöqvist and Tottie, eds., Stockholm, p. 445–448.Google Scholar
  19. Gunne, L.-M., Änggård, E., and Jönsson, L. E., 1970, Blockade of Amphetamine Effects in Human Subject., I.C.A.A. Tongue and Tongue, Lausanne, p. 249–255.Google Scholar
  20. Haertzen, C. A., Hill, H. E., and Belleville, R. E., 1963, “Development of the Addiction Research Center Inventory CARCI. Selection of items that are sensitive to the effects of various drugs,” Psychopharmacologia 4: 155.PubMedCrossRefGoogle Scholar
  21. Hansson, L. C. F., 1967, “Evidence that the central action of (+)-amphetamine mediated via catecholamines,” Psychopharmacologia 10: 289–297.CrossRefGoogle Scholar
  22. Inghe, G., 1969, “The present state of abuse and addiction to stimulant drugs in Sweden,” in: Abuse of Central Stimulants, p. 187 (Sjöqvist, F., and Tottie, M., eds.) Almqvist & Wiksell, Stockholm.Google Scholar
  23. Janssen, P., Niemegeers, C., and Schellekens, K., 1965, “Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data?” Drug Res. (Arsneim.-Forsch.) 15: 104–117.Google Scholar
  24. Jönsson, L. E., Gunne, L.-M., and Änggård, E., 1969, “Effects of alphamethyltyrosine in amphetamine-dependent subjects,” European J. Clin. Pharmacol. 2: 27–29.Google Scholar
  25. Milne, M. D., Scribner, B. H., and Crawford, M. D., 1958, “Non-ionic diffusion and the excretion of weak acids and bases,” Am. J. Med. 24: 709–729.PubMedCrossRefGoogle Scholar
  26. Randrup, A., and Munkvad, I., 1966, “Role of catecholamines in the amphetamine excitatory response,” Nature 211: 540.PubMedCrossRefGoogle Scholar
  27. Rosenberg, D. E., Wolbach, A. B., Miner, E. J., and Isbell, H., 1963, “Observations on direct and cross tolerance with LSD and d-amphetamine in man,” Psychopharmacologia 5: 1–15.PubMedCrossRefGoogle Scholar
  28. Rowland, M., 1969, “Amphetamine blood and urine levels in man,” J. Pharmacol. 58: 508.Google Scholar
  29. Stolk, J. M., and Rech, R. H., 1969, “Effect of reserpine on accumulation and removal of d-amphetamine-3H.,” Biochem. Pharmacol. 18: 2786.PubMedCrossRefGoogle Scholar
  30. Taylor, K. M., and Snyder, S. H., 1970, “Amphetamine differentiation by d-and l-isomers of behavior involving brain norepinephrine and dopamine,” Science 169: 147.CrossRefGoogle Scholar
  31. Weissman, A., Koe, B. K., and Tenen, S., 1966, “Antiamphetamine effects following inhibition of tyrosine hydroxylase,” J. Pharmacol. Exp. Therap. 151: 339–352.Google Scholar

Copyright information

© Springer Science+Business Media New York 1972

Authors and Affiliations

  • Lars-M. Gunne
    • 1
  • Erik Änggård
    • 1
  1. 1.Psychiatric Research CenterUlleraker HospitalUppsalaSweden

Personalised recommendations